The Motley Fool
16 Jul 2026, 03:19 UTC · 2h ago
Is Johnson & Johnson a Buy After Its Latest Earnings Report?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
16 Jul 2026, 03:19 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Johnson & Johnson's Abiomed heart pump sales declined 2% to $440 million, following a previous 16% increase. — The reversal in growth suggests physician concern over a clinical study and indicates a potential long-term demand slump for a key MedTech product.
-0.40Tremfya sales grew 73% to $2 billion, successfully offsetting a 56% decline in Stelara sales. — Strong growth in a new product is critical for mitigating the revenue loss from an aging drug's decline.
+0.30The company's oncology portfolio sales rose 17% to $7.4 billion, led by Darzalex sales growth of nearly 19%. — Robust performance in the high-value oncology sector provides a stable growth engine for the pharmaceutical business.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
J&J reported total Q2 sales of $25.3 billion and non-GAAP net income of $7.08 billion, slightly beating analyst expectations. — While the company beat estimates, the modest nature of the beat failed to drive positive investor sentiment.
+0.10Which stocks this story touches
The stock fell nearly 3% following an earnings report that investors found unappealing despite a double beat on analyst estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Invezz
52m ago
